- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Coherus Announces Strong Early Sales for Pegfilgrastim Biosimilar, Udenyca
In its announcement, the drug maker said that its Udenyca sales are expected to be in the range of $36 million to $38 million.
Coherus BioSciences, maker of the pegfilgrastim biosimilar Udenyca, has announced its preliminary unaudited sales for the first quarter of 2019. In its announcement, the drug maker said that its Udenyca sales are expected to be in the range of $36 million to $38 million.
The company says that it will discuss its sales in further detail after the data are reported in its Form 10-Q for the quarter, and it will provide additional financial updates on May 9, 2019.
The biosimilar developer brought its pegfilgrastim biosimilar to the US market on January 3, 2019, with a comprehensive launch that included 340B hospitals and non-340B hospitals and clinics. The company launched the product at a list price of $4175 per unit, or a 33% discount to the reference pegfilgrastim, Neulasta. Udenyca’s list price matches that of Mylan’s Fulphila, the first pegfilgrastim biosimilar to launch in the United States, although these list prices do not reflect any rebates that may be provided by the respective drug makers.
The early sales numbers for the biosimilar pegfilgrastim reflect the success of what Coherus’ president and chief executive officer, Dennis M. Lanfear, has called the company’s “branded approach” to the product’s launch.
During the recent 37th Annual J.P. Morgan Healthcare Conference, Lanfear said that “Our approach is that of a branded launch…this has never been done before with a biosimilar.” This strategy involves a focus on payers, integrated delivery networks, and group purchasing organizations that consolidate purchasing for clinics and hospitals, as well as provider segments comprising community oncology clinics, 340B hospitals, and non-340B hospitals, he explained.
In addition to Udenyca, Coherus is currently advancing 2 additional late-stage biosimilar programs: an adalimumab biosimilar referencing Humira and an etanercept biosimilar referencing Enbrel. It is also developing ophthalmology biosimilars, including ranibizumab, referencing Lucentis, and aflibercept, referencing Eylea. It is also developing CHS-131, a novel small-molecule agent that is intended to treat both nonalcoholic steatohepatitis and multiple sclerosis.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Expanding Biosimilar Adoption: Insights and Strategies With Dr Sophia Humphreys
September 16th 2024Sophia Humphreys, PharmD, MHA, BCBBS, director of system formulary management at Sutter Health, discusses the challenges of expanding biosimilars into new therapeutic areas and highlights the role of education, competitive pricing, and integrated delivery networks in improving adoption and market growth.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: FDA Clarification Provides New Indications and Process Change for Biosimilars
September 9th 2024Sarfaraz K. Niazi, PhD, explains the FDA's new guidelines on post-approval changes for biosimilars, emphasizing the processes for reporting modifications, comparability assessments, and the potential for biosimilars to introduce new indications or formulation changes, which could significantly impact their market competitiveness and accessibility.
The Role of Coverage Strategies in Biosimilar Market Impact and Cost Savings
September 4th 2024A recent study highlights that although biosimilars have led to significant price reductions, originator products with sole preferred coverage strategies have maintained market share, suggesting that increased biosimilar uptake alone may not fully leverage the market's competitive and cost-saving potential.
